StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.36−0.61 (-1.00%)

Close on Nov 17, 2026Market cap $5.04BP/E –Yield –

PTC Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

PTC Therapeutics's pe ratio was 8.4× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20268.4×−0.5
2025Dec 31, 20258.9×–

More PTC Therapeutics figures

See a number that looks wrong?